PAT² for the quarter grew by +26% YoY to INR 338 Cr

• Gross Revenue stood at INR 1,827 Cr for Q2 FY24, +17% growth YoY & +6% growth QoQ
• Network Operating EBITDA was INR 497 Cr, growth of +21% YoY and+14% QoQ
• Operating Margin stood at 7% versus 27.7% in Q2 FY23 and 26.8% in Q1 FY24
• EBITDA per bed³ improved to INR 0 lakhs in Q2 FY24, from INR 64.3 lakhs in Q2 FY23 and INR 70.4 lakhs in Q1 FY24
• PAT² stood at INR 338 Cr in Q2 FY24 versus INR 267 Cr in Q2 FY23 and INR 291 Cr in Q1 FY24
• Free Cash from Operations⁴ stood at INR 436 Cr in Q2 FY24, of this INR 90 Cr was spent towards ongoing capacity expansion projects; Net Cash surplus⁵ as on Sep 30, 2023 was INR 1,303 Cr
• Bed occupancy in Q2 FY24 stood at 77% and Occupied Bed Days (OBD) grew by +3% YoY
• ARPOB⁶ improved to INR 6k in Q2 FY24 vs. INR 66.0k in Q2 FY23 and 74.8k in Q1 FY24, growth of +13% YoY & flat QoQ
• Free treatment provided to 38,972 patients in OPD and 1,295 patients in IPD from the economically weaker sections

 Max Healthcare Institute Ltd. (MHIL, ‘the Company’), one of the largest private sector healthcare services company in India, announced its financial and operating results for three months ended Sep 30, 2023, today.

Network gross revenue was INR 1,827 Cr, reflecting a growth of +17% YoY and 6% QoQ. All hospitals improved their ARPOB during the period & the overall average growth in ARPOB stood at +13% YoY. Further, the OBDs grew by +3%.

Network Operating EBITDA stood at INR 497 Cr compared to INR 410 Cr in the corresponding quarter last year. This reflects a growth of +21% YoY & +14% QoQ and operating EBITDA margin of 28.7%, compared to 27.7% in Q2 FY23 & 26.8% in Q1 FY24. EBITDA per bed² during the quarter improved to INR 75.0 lakhs, registering a growth of +17% YoY & +7% QoQ.

Profit after tax (PAT)² for the quarter stood at INR 338 Cr compared to INR 267 Cr in Q2 FY23 and INR 291 Cr in Q1 FY24.

Cash flow from operations⁴ stood at INR 436 Cr during the quarter, of which INR ~90 Cr was spent on ongoing capacity expansion projects. Net Cash⁵ surplus at the end of Sep 2023 stood at INR 1,303 Cr, compared to INR 957 Cr at the end of Jun 2023.

Max Shalimar Bagh, with its enhanced bed capacity of 402 beds, reported a YoY Revenue & EBITDA growth of +41% & +48% respectively, at an average bed occupancy of 78%.

International patient revenue grew by +25% YoY and +11% QoQ. The share of international patient revenues stood at ~9% of the hospital revenue during the quarter.

(1) Network includes the Company, its subsidiaries, managed hospitals and partner healthcare facilities | (2) Q2 FY23 includes impact of one time reversal of INR 244 Cr deferred tax liability (net of capital gains tax) pursuant to voluntary liquidation and distribution of assets of a subsidiary on a going concern basis to its holding Company (MHIL ) | (3) Based on Operating EBITDA per OBD (annualised) and excludes Max Lab operations | (4) After Interest, tax, working capital changes and routine capex | (5) After considering term loans, cash credit & put option liability but excludes Lease Liability | (6) Excludes revenue from Max Lab operations

Max Lab (non-captive pathology vertical) reported gross revenue of INR 39 Cr during the quarter, recording a growth of +32% YoY and +15% QoQ on a like-to-like basis¹.

Max@Home gross revenue during Q2 FY24 was INR 42 Cr, a growth of +23% YoY and +8% QoQ.

For the six months ended Sep 2023, the Network gross revenue stood at INR 3,546 Cr representing a growth of ~17% over the corresponding period last fiscal, driven by growth in ARPOB and increase in OBDs.

The Network Operating EBITDA grew by 20% over H1 FY23, and stood at INR 933 Cr. Further the Operating margin for H1 FY24 was 27.8%, compared to 27.1% in H1 FY23.

PAT for H1 FY24 stood at INR 628 Cr, representing a growth of 27% on a like-to-like basis²

Commenting on Q2 results, Mr. Abhay Soi, Chairman and Managing Director, Max Healthcare Institute Ltd., said:

“Q2 results are in line with our expectations and reflect the continuous focus on execution at grass root level. We are well-poised to absorb addition to network bed capacity in the coming years, while we evaluate M&A targets for inorganic growth. I am happy to note that Max Dwarka has applied for occupancy certificate and we look forward to operationalising the hospital in Q4 FY24. We continue to see attractive opportunities for significant investments in the sector.”

Financial and Operational Highlights (on like-to-like basis)¹

Clinical Update:

• Signed MoU with Intuitive to establish Southeast Asia’s 1^st Total Program Observation (TPO) Centre, located at MSSH-Saket, to drive enhancements in patient care using robotic-assisted surgery
• Till date 2,400+ Liver Transplants, ~3,800 Kidney Transplants & 1,740+ Bone Marrow Transplants have been performed
• MSSH-Patparganj successfully removed a large cystic renal tumor using robotic partial nephrectomy, saving 70% of renal parenchyma of the patient
• Cured a 49-year-old patient suffering from last stage renal disease by performing a complex robotic transplant at BLK Max
• Excluding non-recurring revenue and EBITDA from Covid-19 vaccination | (2) Q2 FY23 includes impact of one-time reversal of INR 244 Cr deferred tax liability (net of capital gains tax) pursuant to voluntary liquidation and distribution of assets of a subsidiary on a going concern basis to its holding Company (MHIL) | (3) As a percent of net revenue | (4) After spend of ~INR 90 Cr & ~INR 128 Cr towards capacity expansion projects in Q2 FY24 & H1 FY24 respectively
• MSSH-Dehradun became the 1^st hospital in tri-city  to successfully perform Full Thickness resection of Locally Invasive Rectal Carcinoma on a 78-year-old patient
• Nanavati Max successfully performed a complex liver transplant on a 5-year old patient, with the donor being just 2-years old

Research and Academics:

• Published 107 articles in high impact journals during Q2 FY24
• MoU signed with the Prestigious Royal College of Obstetricians & Gynecologists UK for MRCOG (Membership of Royal College of Obstetrics & Gynecology) training
• 103 clinical trials & 22 grant studies are currently ongoing across Network Hospitals
• ~115 MBBS students currently enrolled for a two-year clinical rotation in collaboration with Lincoln American University
• Total DNB residents across the network is ~440 currently